Abbvie Inc (NYSE:ABBV) shares traded 1.96% higher at $209.03 on Wall Street last session.
ABBV stock price is now 13.76% away from the 50-day moving average and 14.81% away from the 200-day moving average. The market capitalization of the company currently stands at $369.01B.
On December 05, 2024, Daiwa Securities Downgraded its previous ‘Outperform’ rating to ‘Neutral’ on the stock keeping its target price maintained at $180, while ‘Leerink Partners’ rates the stock as ‘Outperform’
In other news, GONZALEZ RICHARD A, Officer bought 92,460 shares of the company’s stock on Feb 28 ’25. The stock was bought for $18,964,882 at an average price of $205.11. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 26 ’25, SVP, CONTROLLER Buckbee Kevin K sold 18,944 shares of the business’s stock. A total of $3,853,372 was realized by selling the stock at an average price of $203.41. This leaves the insider owning 11,496 shares of the company worth $2.4 million. A total of 0.16% of the company’s stock is owned by insiders.
During the past 12 months, Abbvie Inc has had a low of $153.58 and a high of $207.32. As of last week, the company has a debt-to-equity ratio of 20.40, a current ratio of 0.66, and a quick ratio of 0.55.
The net profit margin was 7.52% and return on equity was 61.94% for ABBV. The company reported revenue of $15.1 billion for the quarter, compared to $14.3 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.6 percent.
